With Avastin Approval For Breast Cancer, Will More Patients Hit Price Cap?
Executive Summary
FDA approval of Genentech's Avastin for first-line treatment of metastatic breast cancer may trigger the first significant trial of the biotech's Avastin patient assistance program, which caps annual drug expenditures at $55,000 for approved indications but has not seen much utilization by colorectal or non-small cell lung cancer patients
You may also be interested in...
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.
Genentech May Not Get A Chance To Appeal FDA's Decision To Withdraw Avastin's Breast Cancer Approval
Genentech has been clear that it intends to appeal FDA's determination that the breast cancer indication for Avastin should be revoked, but the agency may not let the appeal go forward.
AVADO Presented At ASCO; But After The Fanfare, What Does It Signify?
CHICAGO - With the positive results of Roche's AVADO study of Avastin in first-line metastatic breast cancer, Roche and Genentech have the value of having a placebo-controlled, double-blind confirmation of bevacizumab's use in that setting. But what the presentation of AVADO at the American Society of Clinical Oncology annual meeting really did was revive debate over the breast cancer approval and raise questions about proper use in that setting